**ONLINE: Supplementary Table** 1 Demographics, baseline characteristics, and medications of 22 pediatric patients with microscopic colitis

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Patient | Sex | Age at diagnosis (years) | Known underlying diagnosis | Prior Medication Exposure  (within 3 months) | Family History | Length of Follow-up (months) | Treatment Course |
| 1 | F | 17.3 | Celiac, DM, CVID | -- | Thyroid, SLE, RA | 86.8 | Nonresponse to mesalamine; mild response from prednisone and bismuth subsalicylate; partial response to octreotide with frequent relapses |
| 2 | F | 17.6 | -- | NSAID, SSRI,  anti-epileptic | -- | 1.7 | Complete response to mesalamine x 6 weeks |
| 3 | M | 17.6 | -- | -- | Thyroid | 4.2 | Nonresponse to mesalamine x 4 months |
| 4 | F | 16.3 | -- | -- | -- | 9.0 | Complete response to prednisone x 10 weeks; partial response to bismuth subsalicylate following relapse |
| 5 | M | 2.1 | Celiac | -- | -- | 9.2 | -- |
| 6 | M | 14.8 | \_ | NSAID, PPI | Asthma | 0.5 | Started on loperamide, with loss to follow-up |
| 7 | F | 5.5 | -- | -- | RA, IBD | 10.8 | Complete response to bismuth subsalicylate x 3 months;  Flared 6 weeks later |
| 8 | F | 17.1 | -- | -- | -- | 1.2 | -- |
| 9 | F | 17.3 | -- | NSAID, PPI, SSRI | Celiac | 24.5 | Nonresponse to mesalamine x 2 weeks; partial response with prednisone & loperamide x10 weeks; partial response to azathioprine x8 weeks.  Nonresponse to bismuth subsalicylate |
| 10 | M | 18.6 | -- | -- | RA, IBD | 18.0 | Complete response to bismuth subsalicylate x 13 weeks; flared 5 months later; partial response with intermittent loperamide |
| 11 | M | 5.8 | -- | -- | IBD | 6.0 | -- |
| 12 | F | 3.3 | -- | NSAID | -- | 0.2 | Started on mesalamine, with loss to follow-up |
| 13 | F | 2.0 | -- | PPI | RA, SLE, IBD | 3.4 | Nonresponse to bismuth subsalicylate and loperamide,  partial response with prednisone x 7 weeks |
| 14 | F | 16.1 | -- | NSAID | -- | 0.5 | Started on loperamide and bismuth subsalicylate, loss to follow-up |
| 15 | F | 3.0 | -- | -- | -- | 26.0 | Complete response to budesonide x 11 weeks |
| 16 | M | 6.9 | *C. difficile* (cleared) | -- | Thyroid, SLE, CTDx | 21.1 | Partial response to budesonide x 4 months, then flared 5 months later |
| 17 | F | 15.9 | DM | PPI | RA, DM, IBD | 30.0 | Nonresponse to bismuth subsalicylate,  partial response to mesalamine x 5 months |
| 18 | F | 5.2 | Celiac | NSAID, PPI,  anti-epileptic | IBD | 17.0 | -- |
| 19 | M | 12.0 | -- | PPI | -- | 9.2 | Started on budesonide, loss to follow-up |
| 20 | F | 17.7 | -- | -- | Thyroid | 0.1 | -- |
| 21 | M | 11.9 | Celiac, *C. jejuni* (cleared) | NSAID | -- | 20.4 | Complete response to prednisone x 2 months; started on mesalamine with loss to follow-up |
| 22 | M | 17.8 | CVID | SSRI |  | 1.8 | Complete response to budesonide and mesalamine x 6 weeks |

*LC lymphocytic colitis, CC collagenous colitis, DM type 1 diabetes mellitus, CVID common variable immunodeficiency, NSAID non-steroidal anti-inflammatory, SSRI selective serotonin*

*re-uptake inhibitor, PPI proton pump inhibitor, SLE systemic lupus erythematosus, RA rheumatoid arthritis, IBD inflammatory bowel disease, CTDx mixed connective tissue disease*